The road to approval: a perspective on the role of icosapent ethyl in cardiovascular risk reduction.
Impact of expanded FDA indication for icosapent ethyl on enhanced cardiovascular residual risk reduction.
Benefits of icosapent ethyl across a range of baseline renal function in patients with established cardiovascular disease or diabetes: results of REDUCE-IT RENAL [abstract FR-OR18].
Substantial cardiovascular benefit from icosapent ethyl in patients with diabetes: REDUCE-IT DIABETES [abstract 627].
Eicosapentaenoic acid (EPA) containing phospholipids modulate membrane structure.
REDUCE-IT: total ischemic events reduced across the full range of baseline LDL cholesterol and other key subgroups.
REDUCE-IT: Accumulation of data across prespecified interim analyses to final results.
Outcomes by baseline statin type.
Treatment with icosapent ethyl to reduce ischemic events in patients with prior percutaneous coronary intervention - insights from REDUCE-IT PCI.